Enliven Therapeutics, Inc.
ELVN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001672619
In the last 90 days, Enliven Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 214 institutions reported holding it in 13F filings for Q2 2026, worth $4.08B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $11.8M in total
- 8
- 13F holdersQ2 2026, +46 vs. previous quarter
- 214
- 13F valueReported value at the end of Q2 2026
- $4.08B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ELVN, Q2 2026
No superinvestor reported holding ELVN at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Enliven Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 2026 (view filing)5:23 PM ET | Sep 17 | 4 days | Hohl BenjaminCHIEF FINANCIAL OFFICER | SSale | −6.02K | $50.35 | −$303.0K | −13.7%38.0K after | 3 lots10b5-1 |
| Sep 21, 2026 (view filing)5:22 PM ET | Sep 17 | 4 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −5.00K | $50.35 | −$251.8K | −16.7%25.0K after | 3 lots10b5-1 |
| Aug 19, 2026 (view filing)4:17 PM ET | Aug 17 | 2 days | Hohl BenjaminCHIEF FINANCIAL OFFICER | SSale | −6.02K | $58.58 | −$352.6K | −13.1%40.0K after | 2 lots10b5-1 |
| Aug 19, 2026 (view filing)4:16 PM ET | Aug 17 | 2 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −5.00K | $58.59 | −$292.9K | −16.7%25.0K after | 2 lots10b5-1 |
| Aug 6, 2026 (view filing)8:18 PM ET | Aug 4 | 2 days | Derynck Mika KDirector | SSale | −158.8K | $60.21 | −$9.56M | −100.0%0 after | 10b5-1 |
| Jul 21, 2026 (view filing)5:24 PM ET | Jul 17 | 4 days | Hohl BenjaminCHIEF FINANCIAL OFFICER | SSale | −6.02K | $52.64 | −$316.8K | −11.6%46.1K after | 5 lots10b5-1 |
| Jul 21, 2026 (view filing)5:23 PM ET | Jul 17 | 4 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −5.00K | $52.67 | −$263.4K | −16.7%25.0K after | 5 lots10b5-1 |
| Jul 8, 2026 (view filing)5:15 PM ET | Jul 6 | 2 days | Kunkel Lori AnneDirector | SSale | −10.0K | $50.49 | −$504.9K | −19.3%41.9K after | 2 lots10b5-1 |
| Jun 24, 2026 (view filing)7:19 PM ET | Jun 22 | 2 days | OrbiMed Advisors LLC and 2 others10% Owner | SSale | −860.1K | $45.36 | −$39.0M | −11.6%6.56M after | 4 lots |
| Jun 22, 2026 (view filing) | Jun 17 | 5 days | Hohl BenjaminCHIEF FINANCIAL OFFICER | SSale | −6.02K | $43.80 | −$263.6K | −10.6%51.0K after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Enliven Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 10,025,017 | $508.8M | 0.02% | +3,195,771+46.8% | Added |
| OrbiMed Advisors LLC | 6,776,632 | $343.9M | 6.51% | −1,182,906−14.9% | Reduced |
| Polar Capital Holdings Plc | 6,430,636 | $326.4M | 0.92% | +1,364,703+26.9% | Added |
| BlackRock, Inc. | 4,359,704 | $221.3M | 0.00% | +674,997+18.3% | Added |
| Vestal Point Capital, LP | 4,000,000 | $203.0M | 4.74% | +750,000+23.1% | Added |
| Commodore Capital LP | 3,275,000 | $166.2M | 9.90% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 2,903,907 | $147.4M | 0.01% | +2,806,160+2,870.8% | Added |
| Vanguard Capital Management LLC | 2,569,002 | $130.4M | 0.00% | +400,840+18.5% | Added |
| Citadel Advisors LLC | 2,068,992 | $105.0M | 0.06% | +325,077+18.6% | Added |
| Fairmount Funds Management LLC | 1,855,644 | $94.2M | 6.22% | 00.0% | Unchanged |